COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00476034
Recruitment Status : Completed
First Posted : May 21, 2007
Last Update Posted : May 21, 2012
Information provided by (Responsible Party):

Brief Summary:
This 39-week, active controlled, study is designed to assess long-term efficacy, safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis (OA) of the knee who participated in the 13-week core CCOX189A2361 study.

Condition or disease Intervention/treatment Phase
Osteoarthritis Drug: lumiracoxib Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1312 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A 39-week, Double-blind, Active-controlled Extension to CCOX189A2361, a 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator
Study Start Date : December 2003
Actual Primary Completion Date : November 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Primary Outcome Measures :
  1. To compare lumiracoxib 100mg od to celecoxib 200mg od in treating osteoarthritis (OS) of the target knee with respect to:
  2. Overall OA pain intensity in the target knee on a 0-100 mm Visual Analog Scale (VAS) at 26 weeks.
  3. Patient's global assessment of disease activity on a 0-100mm VAS at 26 weeks.
  4. Patient's functional status using the WOMAC total score at 26 weeks

Secondary Outcome Measures :
  1. To assess the safety and tolerability profile of lumiracoxib as compared to celecoxib
  2. To assess the efficacy of lumiracoxib as compared to celecoxib with respect to:
  3. Overall OA pain intensity on a 0-100 mm VAS by visit
  4. Patient's global assessment of disease activity by visit
  5. Physician's global assessment of disease activity by visit
  6. Patient's functional status using the WOMAC 3.1 LK sub-scale scores and total score by visit
  7. Usage of rescue medication
  8. Response to treatment according to OARSI criteria by visit

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Any patient who completed the core study 2361 may enter the extension trial upon signing informed consent. A patient is defined as completing if he/she completed the core study 2361 up to and including Visit 6 (week 13) without a major protocol violation.

Exclusion Criteria:

  • Those patients for whom continued treatment in the extension study is not considered appropriate by the treating physician
  • Those patients who were non-compliant or who demonstrated a major protocol violation in the core study.

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00476034

Layout table for location information
Novartis Investigative Site
Malvern, Australia
Novartis Investigative Site
Vienna, Austria
Czech Republic
Novartis Investigative Site
Prague, Czech Republic
Novartis Investigative Site
Turku, Finland
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Haifa, Israel
Novartis Investigative Site
Lisse, Netherlands
New Zealand
Novartis Investigative Site
Rotorua, New Zealand
Novartis Investigative Site
Poznan, Poland
Novartis Investigative Site
Bratislava, Slovakia
South Africa
Novartis Investigative Site
Johannesburg, South Africa
Novartis Investigative Site
Sevilla, Spain
Novartis Investigative Site
Uppsala, Sweden
Novartis Investigative Site
Izmir, Turkey
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Novartis Identifier: NCT00476034    
Other Study ID Numbers: CCOX189A2361E1
First Posted: May 21, 2007    Key Record Dates
Last Update Posted: May 21, 2012
Last Verified: May 2012
Keywords provided by Novartis:
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents